Onkojenik Virüsler

MacLennan SA, Marra MA. Oncogenic Viruses and the Epigenome: How Viruses Hijack Epigenetic Mechanisms to Drive Cancer. International Journal of Molecular Sciences. 2023 May 31;24(11):9543.

Krump NA, You J. Molecular mechanisms of viral oncogenesis in humans. Nature Reviews Microbiology. 2018 Nov;16(11):684-698.

Chuang YC, Tsai KN, Ou JJ. Pathogenicity and virulence of Hepatitis B virus. Virulence. 2022 Dec;13(1):258-296.

Yuen, MF., Chen, DS., Dusheiko, G. et al. Hepatitis B virus infection. Nat Rev Dis Primers 4, 18035 (2018).

Zhang M, Chen H, Liu H, Tang H. The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy. Biomark Res. 2024 Aug 15;12(1):84.

Agustiningsih A, Rasyak MR, Turyadi, Jayanti S, Sukowati C. The oncogenic role of hepatitis B virus X gene in hepatocarcinogenesis: recent updates. Explor Target Antitumor Ther. 2024;5(1):120-134.

Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Geneva: World Health Organization; 2024.

Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization; 2024.

Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020 Feb 26;33(2):e00046-19.

Roger S, Ducancelle A, Le Guillou-Guillemette H, Gaudy C, Lunel F. HCV virology and diagnosis. Clin Res Hepatol Gastroenterol. 2021 May;45(3):101626.

Li HC, Yang CH, Lo SY. Hepatitis C Viral Replication Complex. Viruses. 2021 Mar 22;13(3):520.

Khatun M, Ray R, Ray RB. Hepatitis C virus associated hepatocellular carcinoma. Adv Cancer Res. 2021;149:103-142.

Heredia-Torres TG, Rincón-Sánchez AR, Lozano-Sepúlveda SA, Galan-Huerta K, Arellanos-Soto D, García-Hernández M, Garza-Juarez AJ, Rivas-Estilla AM. Unraveling the Molecular Mechanisms Involved in HCV-Induced Carcinogenesis. Viruses. 2022 Dec 11;14(12):2762.

Accelerating access to hepatitis C diagnostics and treatment: overcoming barriers in low- and middle-income countries. Global progress report 2020. Geneva: World Health Organization; 2021

Brites C, Grassi MF, Quaresma JAS, Ishak R, Vallinoto ACR. Pathogenesis of HTLV-1 infection and progression biomarkers: An overview. Braz J Infect Dis. 2021 May-Jun;25(3):101594.

Nozuma S, Kubota R, Jacobson S. Human T-lymphotropic virus type 1 (HTLV-1) and cellular immune response in HTLV-1-associated myelopathy/tropical spastic paraparesis. J Neurovirol. 2020 Oct;26(5):652-663.

Aghajanian S, Teymoori-Rad M, Molaverdi G, Mozhgani SH. Immunopathogenesis and Cellular Interactions in Human T-Cell Leukemia Virus Type 1 Associated Myelopathy/Tropical Spastic Paraparesis. Front Microbiol. 2020 Dec 22;11:614940.

Zhang LL, Wei JY, Wang L, Huang SL, Chen JL. Human T-cell lymphotropic virus type 1 and its oncogenesis. Acta Pharmacol Sin. 2017 Aug;38(8):1093-1103.

Eusebio-Ponce E, Anguita E, Paulino-Ramirez R, Candel FJ. HTLV-1 infection: An emerging risk. Pathogenesis, epidemiology, diagnosis and associated diseases. Rev Esp Quimioter. 2019 Dec;32(6):485-496.

Ferreira QR, Novaes AF, Santana CS, Umeda AS, de Souza Nascimento JO, de Freitas Santos JPM, Fernandes LA, Moura MN, Amorim RL, Cavalcanti VN, da Cruz ALB, Barreto FK, Costa DT. Neurological aspects of HTLV-1 infection: symptoms in apparently asymptomatic carriers. J Neurovirol. 2024 Apr 23.

Gessain A, Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 2012; 3: 388.

El Hajj H, Bazarbachi A. Interplay between innate immunity and the viral oncoproteins Tax and HBZ in the pathogenesis and therapeutic response of HTLV-1 associated adult T cell leukemia. Front Immunol. 2022 Jul 22;13:957535.

Sertöz R, Turhan A, Bozkurt H, Samlıoğlu P, Değirmenci A, Aydınok Y, et al. Investigation of anti-HTLV I/II seroprevalence in healthy blood donors in Izmir region, Turkey. Mikrobiyol Bul 2010; 44(4): 579-84.

Isache C, Sands M, Guzman N, Figueroa D. HTLV-1 and HIV-1 co-infection: a case report and review of the literature. IDCases 2016; 4: 5355.

World Health Organization. (‎2021)‎. Human T-lymphotropic virus type 1: technical report. World Health Organization.

Mesnard JM, Barbeau B, Césaire R, Péloponèse JM. Roles of HTLV-1 basic Zip Factor (HBZ) in Viral Chronicity and Leukemic Transformation. Potential New Therapeutic Approaches to Prevent and Treat HTLV-1-Related Diseases. Viruses. 2015 Dec 9;7(12):6490-505.

Damania B, Kenney SC, Raab-Traub N. Epstein-Barr virus: Biology and clinical disease. Cell. 2022 Sep 29;185(20):3652-3670.

Rozman M, Korać P, Jambrosic K, Židovec Lepej S. Progress in Prophylactic and Therapeutic EBV Vaccine Development Based on Molecular Characteristics of EBV Target Antigens. Pathogens. 2022 Jul 30;11(8):864.

Smatti MK, Al-Sadeq DW, Ali NH, Pintus G, Abou-Saleh H, Nasrallah GK. Epstein-Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update. Front Oncol. 2018 Jun 13;8:211.

Münz C. Latency and lytic replication in Epstein-Barr virus-associated oncogenesis. Nat Rev Microbiol. 2019 Nov;17(11):691-700.

Huang W, Bai L, Tang H. Epstein-Barr virus infection: the micro and macro worlds. Virol J. 2023 Oct 2;20(1):220.

van der Meulen E, Anderton M, Blumenthal MJ, Schäfer G. Cellular Receptors Involved in KSHV Infection. Viruses. 2021 Jan 17;13(1):118.

Casper C, Corey L, Cohen JI, Damania B, Gershon AA, Kaslow DC, Krug LT, Martin J, Mbulaiteye SM, Mocarski ES, Moore PS, Ogembo JG, Phipps W, Whitby D, Wood C. KSHV (HHV8) vaccine: promises and potential pitfalls for a new anti-cancer vaccine. NPJ Vaccines. 2022 Sep 20;7(1):108.

Weed DJ, Damania B. Pathogenesis of Human Gammaherpesviruses: Recent Advances. Curr Clin Microbiol Rep. 2019;6(3):166-174.

Iftode N, Rădulescu MA, Aramă ȘS, Aramă V. Update on Kaposi sarcoma-associated herpesvirus (KSHV or HHV8) - review. Rom J Intern Med. 2020 Dec 17;58(4):199-208.

Cesarman E, Chadburn A, Rubinstein PG. KSHV/HHV8-mediated hematologic diseases. Blood. 2022 Feb 17;139(7):1013-1025.

Schneider JW, Dittmer DP. Diagnosis and Treatment of Kaposi Sarcoma. Am J Clin Dermatol. 2017 Aug;18(4):529-539.

Coen N, Duraffour S, Snoeck R, Andrei G. KSHV Targeted Therapy: An Update on Inhibitors of Viral Lytic Replication. Viruses. 2014; 6(11):4731-4759.

Mlynarczyk-Bonikowska B, Rudnicka L. HPV Infections—Classification, Pathogenesis, and Potential New Therapies. International Journal of Molecular Sciences. 2024; 25(14):7616.

Oyouni AAA. Human papillomavirus in cancer: Infection, disease transmission, and progress in vaccines. J Infect Public Health. 2023 Apr;16(4):626-631.

Balhara N, Yadav R, Ranga S, Ahuja P, Tanwar M. Understanding the HPV associated cancers: A comprehensive review. Mol Biol Rep. 2024 Jun 14;51(1):743.

Rosendo-Chalma P, Antonio-Véjar V, Ortiz Tejedor JG, Ortiz Segarra J, Vega Crespo B, Bigoni-Ordóñez GD. The Hallmarks of Cervical Cancer: Molecular Mechanisms Induced by Human Papillomavirus. Biology (Basel). 2024 Jan 27;13(2):77.

McBride AA. Human malignancies associated with persistent HPV infection. Oncologist. 2024 Jun 3;29(6):457-464.

Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: World Health Organization; 2020.

McBride AA. Oncogenic human papillomaviruses. Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732):20160273.

Pešut E, Đukić A, Lulić L, Skelin J, Šimić I, Milutin Gašperov N, Tomaić V, Sabol I, Grce M. Human Papillomaviruses-Associated Cancers: An Update of Current Knowledge. Viruses. 2021 Nov 6;13(11):2234.